Boosting translational cancer research

Monday, 13 June, 2016
Developing new anti-cancer treatments is expensive, and national, public funding organisations across Europe dedicate substantial resources to this task. Linking their research programmes helps to ensure these funds are used to best effect. Transcan is now continuing as the Transcan-2 network, fostering long-term transnational synergy.

Transcan was set up in 2011 by public funding organisations supporting translational cancer research — research that aims to develop promising scientific leads into new ways of predicting, detecting and treating cancer. It spans 15 EU countries as well as Israel, Norway, Taiwan and Turkey. The partners funded 30 projects with a total of €33 million from national research budgets. Projects focus on various aspects of cancer prevention as well as biomarkers that enable personalised medicine.

Read more

ERA-NET: Aligning national/regional translational cancer research programmes and activities
Project Acronym: